Patents by Inventor Philip Wilson Howard

Philip Wilson Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11370801
    Abstract: A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y? are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: June 28, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Stephen John Gregson
  • Publication number: 20220160881
    Abstract: A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 26, 2022
    Inventors: Philip Wilson Howard, Thais Cailleau
  • Publication number: 20220135594
    Abstract: A method of synthesising a compound of formula (I) from a compound of formula (II) wherein R2 is phenyl, substituted at either the meta- or para-position by the group (III) where Q is an amino acid residue (—C(?O)—X1—NH—), a di-amino acid residue (—C(?O)—X1—X2—NH—) or a tri-amino acid residue (—C(?O)—X1—X2—X3—NH—); ProtN3 is an amino protecting group; R2pre is phenyl, substituted at the same position as R2 by —NH2; comprising reacting a compound of formula (II) with a compound of formula (IV) in the presence of HATU in dichloromethane or chloroform or a mixture thereof.
    Type: Application
    Filed: February 25, 2020
    Publication date: May 5, 2022
    Inventors: Philip Wilson HOWARD, Thais CAILLEAU
  • Publication number: 20210380605
    Abstract: A compound of formula (I) and salts and solvates thereof, wherein RL is a linker for connection to a cell binding agent, which is formula (IIa) wherein Q is a tripeptide residue of formula (A), where x is 1 or 2, —C(?O)-Qx-NH— is a dipeptide residue; X is: formula (B), where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5; and GL is a linker for connecting to a Ligand Unit.
    Type: Application
    Filed: October 18, 2019
    Publication date: December 9, 2021
    Inventors: Philip Wilson HOWARD, Ian HUTCHINSON, Luke MASTERSON
  • Publication number: 20210322401
    Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 21, 2021
    Inventors: Philip Wilson HOWARD, Niall DICKINSON, Thais CAILLEAU, Luke MASTERSON, William GOUNDRY
  • Publication number: 20210316006
    Abstract: A compound of formula (I) wherein RL is a linker for connection to a cell binding agent.
    Type: Application
    Filed: October 18, 2019
    Publication date: October 14, 2021
    Inventors: Philip Wilson HOWARD, Ian HUTCHINSON
  • Patent number: 11135303
    Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 5, 2021
    Assignee: Medimmune Limited
    Inventors: John A. Flygare, Janet L. Gunzner-Toste, Thomas Pillow, Philip Wilson Howard, Luke Masterson
  • Publication number: 20210290776
    Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
    Type: Application
    Filed: April 6, 2021
    Publication date: September 23, 2021
    Inventor: Philip Wilson HOWARD
  • Publication number: 20210187117
    Abstract: A conjugate of formula (I), wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R10 is OH, and R11 is formula (A): p is an integer of from 1 to 20.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 24, 2021
    Inventors: Philip Wilson Howard, Elizabeth Dunny, Luke Masterson
  • Publication number: 20210137940
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Application
    Filed: August 6, 2020
    Publication date: May 13, 2021
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD
  • Patent number: 10994023
    Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: May 4, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Publication number: 20210113587
    Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Application
    Filed: August 28, 2020
    Publication date: April 22, 2021
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD, John HARTLEY
  • Publication number: 20210079023
    Abstract: A compound with the formula I: (I) and salts and solvates thereof, wherein: R? is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.
    Type: Application
    Filed: April 12, 2019
    Publication date: March 18, 2021
    Inventors: Philip Wilson Howard, Niall John Dickinson
  • Publication number: 20200405880
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 31, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Publication number: 20200399365
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Application
    Filed: November 14, 2019
    Publication date: December 24, 2020
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD
  • Publication number: 20200345861
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Patent number: 10799596
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 13, 2020
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 10799595
    Abstract: A compound of formula (I): (I) and its conjugates.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 13, 2020
    Assignee: MedImmune Limited
    Inventors: Philip Wilson Howard, Stephen John Gregson
  • Publication number: 20200306385
    Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
    Type: Application
    Filed: May 26, 2020
    Publication date: October 1, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Publication number: 20200306243
    Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.
    Type: Application
    Filed: March 23, 2020
    Publication date: October 1, 2020
    Inventors: Philip Wilson Howard, Niall Dickinson, Thais Cailleau, Luke Masterson, William Goundry